Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Natalie E. Talbot"'
For a therapeutic monoclonal antibody (mAb) to reach the clinic, the molecule must be produced at an appropriate yield and quality, then formulated to maintain efficacy and stability. The formation of subvisible particles (SVPs) can impact product st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43e090ad47480759fecf89d3b9a10b96
Publikováno v:
Biotechnology Journal; Oct2019, Vol. 14 Issue 10, pN.PAG-N.PAG, 1p
